Skip to main content
Veterinary Medicines

Wellplus Flavoured Tablets

Authorised
  • Febantel
  • Pyrantel embonate
  • Praziquantel

Product identification

Medicine name:
Wellplus Flavoured Tablets
Wellplus tabletten met smaakstof voor honden
Active substance:
  • Febantel
  • Pyrantel embonate
  • Praziquantel
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Febantel
    150.00
    milligram(s)
    /
    1.00
    Tablet
  • Pyrantel embonate
    144.00
    milligram(s)
    /
    1.00
    Tablet
  • Praziquantel
    50.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AA30
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • box containing 300 tablets (30 blisters)
  • box containing 100 tablets (10 blisters)
  • box containing 50 tablets (5 blisters)
  • box containing 20 tablets (2 blisters)
  • box containing 10 tablets (1 blister)
  • box containing 2 tablets (1 blister)

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Divasa Farmavic S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Divasa Farmavic S.A.
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 112912
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0163/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Germany
  • Greece
  • Ireland
  • Netherlands
  • Poland
  • Portugal
  • Slovakia
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/02/2022

eu-PUAR-wellplus-flavoured-tablets-en.pdf

English (PDF)
Published on: 11/04/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."